Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

NCT03829332

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Alaska Clinical Research Center ( Site 0511) Anchorage, Alaska, United States
  • Ironwood Cancer & Research Centers ( Site 0541) Chandler, Arizona, United States
  • CBCC Global Research, Inc. ( Site 0532) Bakersfield, California, United States
  • Scripps Cancer Center ( Site 0521) La Jolla, California, United States
View all 162 locations
View Trial Details
Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

NCT03820986

Conditions
Malignant Melanoma, Melanoma, Neoplasms, +11 more
Locations
  • The Angeles Clinic and Research Institute ( Site 0707) Los Angeles, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0704) San Francisco, California, United States
  • California Pacific Medical Center Research Institute ( Site 0705) San Francisco, California, United States
  • John Wayne Cancer Institute ( Site 0706) Santa Monica, California, United States
View all 119 locations
View Trial Details
Completed

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

NCT03829319

Conditions
Nonsquamous Non-small Cell Lung Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • El Camino Hospital Cancer Center ( Site 0529) Mountain View, California, United States
  • Yale University ( Site 0519) New Haven, Connecticut, United States
  • Holy Cross Hospital ( Site 0512) Fort Lauderdale, Florida, United States
  • Mercy Health-Paducah Medical Oncology and Hematology ( Site 0570) Paducah, Kentucky, United States
View all 158 locations
View Trial Details
Completed

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

NCT03713593

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • The University of Arizona Cancer Center - North Campus ( Site 0621) Tucson, Arizona, United States
  • City of Hope Comprehensive Cancer Center ( Site 0587) Duarte, California, United States
  • Scripps Health ( Site 0644) La Jolla, California, United States
  • Pacific Hematology Oncology Associates ( Site 0588) San Francisco, California, United States
View all 172 locations
View Trial Details
Completed

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

NCT03598608

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +9 more
Locations
  • Banner MD Anderson Cancer Center ( Site 0020) Gilbert, Arizona, United States
  • City of Hope ( Site 0001) Duarte, California, United States
  • Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007) Los Angeles, California, United States
  • Pacific Cancer Care ( Site 0006) Monterey, California, United States
View all 25 locations
View Trial Details
Completed

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

NCT04776148

Conditions
Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +9 more
Locations
  • Pacific Cancer Care ( Site 0031) Monterey, California, United States
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0021) Marietta, Georgia, United States
  • University of Chicago Medical Center-Medicine - Section of Hematology/Oncology - Gastrointestinal P Chicago, Illinois, United States
  • MFSMC-HJWCI-Oncology Research ( Site 0012) Baltimore, Maryland, United States
View all 95 locations
View Trial Details
Completed

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +4 more
Locations
  • Banner MD Anderson Cancer Center ( Site 0016) Gilbert, Arizona, United States
  • Community Cancer Institute ( Site 0777) Clovis, California, United States
  • University of California Irvine Medical Center ( Site 0078) Orange, California, United States
  • John Wayne Cancer Institute ( Site 0017) Santa Monica, California, United States
View all 194 locations
View Trial Details
Completed

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

NCT03635567

Conditions
Cervical Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • Alaska Women's Cancer Care ( Site 1770) Anchorage, Alaska, United States
  • Arizona Oncology Associates, PC- HAL ( Site 8005) Phoenix, Arizona, United States
  • UC Irvine Health ( Site 1796) Orange, California, United States
  • Smilow Cancer Hospital at Yale New Haven ( Site 1809) New Haven, Connecticut, United States
View all 149 locations
View Trial Details

Related conditions